The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line FOLFOX therapy for advanced esophageal squamous cell carcinoma: Multicenter prospective study in Japan.
 
Kunihiro Fushiki
No Relationships to Disclose
 
Takahiro Tsushima
Honoraria - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Yasuhiro Tsubosa
No Relationships to Disclose
 
Akifumi Notsu
No Relationships to Disclose
 
Shun Yamamoto
Honoraria - Bristol-Myers Squibb Japan; Merck Sharp and Dohme; Ono Pharmaceutical; Taiho Pharmaceutical
 
Izuma Nakayama
No Relationships to Disclose
 
Hiroshi Imazeki
No Relationships to Disclose
 
Yoichi Hamai
No Relationships to Disclose
 
Masaaki Motoori
No Relationships to Disclose
 
Motoo Nomura
Honoraria - Bristol-MyersSquibbK.K.; MSD; ONOPHARMACEUTICALCO.,LTD.
 
Kohei Nakachi
No Relationships to Disclose
 
Soichi Fumita
No Relationships to Disclose
 
Satoshi Otsu
No Relationships to Disclose
 
Yoshihiro Tanaka
No Relationships to Disclose
 
Kentaro Murakami
No Relationships to Disclose
 
Mitsuhiro Furuta
Honoraria - Bristol-Myers Squibb Company; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Hiroya Takeuchi
Honoraria - Abbott Japan; Bristol-Myers Squibb Japan; Daiichi Sankyo/Astra Zeneca; EA Pharma; Hisamitsu Pharmaceutical; Intuitive Surgical; Johnson & Johnson/MedTech; Kaken Pharmaceutical; Medicon; Medtronic; Miyarisan pharmaceutical; MSD K.K; Nichiiko K.K.; Ono Pharmaceutical; Otsuka; Otsuka; Taiho Pharmaceutical; Tsumura & Co.
Research Funding - Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Johnson & Johnson/MedTech; Kaken Pharmaceutical; Kyowa Hakko Kirin K. K.; Lilly Japan; Otsuka; Taiho Pharmaceutical
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)